Purpose Despite treatment, prognosis of unresectable squamous cell carcinoma of the head
and neck (SCCHC) is dismal. Cetuximab therapy has proven to increase the clinical activity …

Background Methotrexate in recurrent or metastatic (R/M) squamous cell carcinoma of the
head and neck (SCCHN) has limited progression‐free survival (PFS) benefit. We …

Cetuximab is typically administered on a weekly schedule for patients with recurrent or
metastatic head and neck squamous cell cancer (HNSCC). This study explores cetuximab …

目的观察西妥昔单抗联合放化疗治疗晚期头颈部恶性肿瘤(HNSCC) 的有效性和安全性.
方法2007 年11 月至2010 年5 月经病理证实的26 例晚期HNSCC 患者, 接受西妥昔单抗联合放 …

Background We investigated the tolerability of cetuximab plus radiotherapy in Japanese
patients with untreated locally advanced squamous cell carcinoma of the head and neck …

Cetuximab is a recombinant chimeric human murine immunoglobulin G1 antibody that binds
to the extra-cellular domain of epidermal growth factor receptor with a higher affinity than …

On the other side of the debate, critics point to the limitations of this study, which did not
directly compare cetuximab to cisplatin, and the lack of any further phase III studies. They …

Surgery and radiotherapy are the standard treatment options for patients with squamous cell
carcinoma of the head and neck (SCCHN). Chemotherapy and chemoradiotherapy are new …

Background Cetuximab, in combination with platinum chemotherapy plus 5-fluoruracil (5-
FU), is approved for the first-line treatment of recurrent/metastatic squamous cell carcinoma …

Objectives To examine the impact of epidermal growth factor receptor (EGFR) expression
level on the efficacy of monoclonal antibodies against the EGFR. Methods In four human …